African Cancer Genome: GMD

Launched by FOX CHASE CANCER CENTER · Feb 22, 2023

Keywords

ClinConnect Summary

The African Cancer Genome study is a clinical trial aimed at understanding the genetic and molecular factors that contribute to breast and prostate cancer in people of African ancestry. Researchers from the African Caribbean Cancer Consortium (AC3) are recruiting participants from various countries, including the Bahamas, Kenya, and the United States. The study will examine how genetic changes and social factors, like lifestyle and health conditions, influence cancer development. To take part, individuals must be between 18 and 85 years old and have a confirmed diagnosis of breast or prostate cancer.

Participants can expect to provide blood samples and tissue from their tumors, which will be analyzed for specific genetic markers. This study is looking for both men and women, and it welcomes those with a history of cancer. However, anyone under 18, incarcerated, or whose medical decisions are made by someone else will not be eligible. By joining this trial, participants will help researchers gather important information that could lead to better treatments and understanding of cancer in people of African descent.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female patients, 18-85 years of age, diagnosed with a pathologically confirmed cancer at any stage at diagnosis. Participant can have a history of a previous cancer we will control for previous history of cancer diagnosis in our analysis.
• Exclusion Criteria:
• • Patients age \<18 year, incarcerated patients, and patients whose medical decisions are made by proxy will be excluded.